MiNK Therapeutics (INKT) director sells 500 shares in open trades

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. director Ryan Barbara reported selling a total of 500 shares of common stock in open-market transactions. The sales occurred on February 27, 2026 for 400 shares at $10.8583 per share and on March 2, 2026 for 100 shares at $10.8258 per share. After these trades, Barbara directly owned 21,906 shares of MiNK Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		S		400	D	$10.8583	22,006	D
Common Stock	03/02/2026		S		100	D	$10.8258	21,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Austin Charette as Attorney-in-Fact for Barbara Ryan	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MiNK Therapeutics (INKT) report for Ryan Barbara?

MiNK Therapeutics reported that director Ryan Barbara sold 500 shares of common stock in open-market transactions. These Form 4 disclosures show two sales totaling 500 shares, reflecting routine insider activity rather than a change in company operations or strategy.

On what dates did Ryan Barbara sell MiNK Therapeutics (INKT) shares and at what prices?

Ryan Barbara sold MiNK Therapeutics common stock on February 27, 2026 and March 2, 2026. The 400-share sale priced at $10.8583 per share and the 100-share sale priced at $10.8258 per share, both reported as open-market transactions under code “S.”

How many MiNK Therapeutics (INKT) shares did Ryan Barbara sell in this Form 4?

The Form 4 shows that director Ryan Barbara sold a total of 500 MiNK Therapeutics common shares. This consisted of a 400-share open-market sale on February 27, 2026 and a 100-share open-market sale on March 2, 2026, all classified as non-derivative transactions.

How many MiNK Therapeutics (INKT) shares does Ryan Barbara hold after these sales?

After the reported open-market sales, Ryan Barbara directly holds 21,906 shares of MiNK Therapeutics common stock. This post-transaction ownership figure reflects the remaining non-derivative shares reported as directly owned following the 400-share and 100-share sales disclosed in the Form 4.

Were the MiNK Therapeutics (INKT) insider transactions reported as buys or sells?

Both transactions were reported as sales of MiNK Therapeutics common stock. The Form 4 classifies them under transaction code “S” as open-market or private sales, with a total of 500 shares sold and no corresponding acquisitions or grants reported in this filing.